FDA’s Oncologic Drugs Advisory Committee on May 2 will consider approval of Delcath Systems Inc.’s chemosaturation system Melblez Kit for a narrower indication than originally requested by the company, in part due to advances in the treatment of melanoma.
ODAC will discuss the use of Melblez Kit (Melblez (melphalan) injection for use with the Delcath Hepatic Delivery System), a...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?